Company / Cash & Equivalents
bioAffinity Technologies, Inc. Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$6.4M
FY2025
5-year range
$1.1M / $11.4M
FY2022-FY2025
Trend
+483.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +484% YoY in FY2025, a notable deviation from the 3-year average annual change of +116%.
Based on SEC 10-K filings.
$6M in FY2025 with a 3-year CAGR of -17.3%.
Improved from $3M to $6M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -17.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -17.3%, indicating a declining trend.
- In FY2025, cash & equivalents increased 483.5% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.4M | +483.5% |
| FY2024 | $1.1M | -60.8% |
| FY2023 | $2.8M | -75.3% |
| FY2022 | $11.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026